Brief: Lee's Pharmaceutical Says Fondaparinux Sodium Injection Got Approval For Drug Registration From China's NMPA
05/02/2021 14:34
Feb 5 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* FONDAPARINUX SODIUM INJECTION OBTAINED APPROVAL FOR DRUG
REGISTRATION FROM NMPA OF PRC
Source text for Eikon: ID:nHKS8DsYFr
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lees Pharmaceutical Holdings
See all newsBrief: Lee's Pharmaceutical Announces Share Repurchase Program Under Repurchase Mandate
Brief: Lee's Pharmaceutical To Receive Funding From Gates Foundation For Synthetic Surfactant Project
Brief: Lee's Pharmaceutical Says Zhaoke Hefei To Contribute Rmb25 Million To Partnership Fund
Brief: Lee's Pharmaceutical Declares Final Dividend Of HK2.3 Cents Per Share
Brief: Lee's Pharmaceutical Reports Approval Of Intrarosa By NMPA